Literature DB >> 32514100

Targeted degraders clear first safety hurdles.

Asher Mullard.   

Abstract

Year:  2020        PMID： 32514100     DOI： 10.1038/d41573-020-00109-w

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  4 in total

Review 1.  Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.

Authors:  Yundong He; Weidong Xu; Yu-Tian Xiao; Haojie Huang; Di Gu; Shancheng Ren
Journal:  Signal Transduct Target Ther       Date:  2022-06-24

2.  New therapeutic modalities in drug discovery and development: Insights & opportunities.

Authors:  Manfred Kansy; Giulia Caron
Journal:  ADMET DMPK       Date:  2021-12-15

3.  Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer.

Authors:  Ying Z Mazzu; Yu-Rou Liao; Subhiksha Nandakumar; Lina E Jehane; Richard P Koche; Sai Harisha Rajanala; Ruifang Li; HuiYong Zhao; Travis A Gerke; Goutam Chakraborty; Gwo-Shu Mary Lee; Gouri J Nanjangud; Anuradha Gopalan; Yu Chen; Philip W Kantoff
Journal:  Oncogene       Date:  2021-11-20       Impact factor: 8.756

4.  PROTAC-DB: an online database of PROTACs.

Authors:  Gaoqi Weng; Chao Shen; Dongsheng Cao; Junbo Gao; Xiaowu Dong; Qiaojun He; Bo Yang; Dan Li; Jian Wu; Tingjun Hou
Journal:  Nucleic Acids Res       Date:  2021-01-08       Impact factor: 16.971
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.